HR 5272 · 107th Congress 2001–2003, ended

Prescription Drug Fair Competition Act of 2002

Latest action · Jul 29, 2002 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJul 26, 2002
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Prescription Drug Fair Competition Act of 2002 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning the timing of generic drug availability.

Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents).

Makes failure to timely register a bar to civil actions for patent infringement.

Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim.

Prohibits (for subsequently issued patents) an extension of the 30 month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer.

Makes failure to timely file a civil action for infringement a bar to later action.

Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.

Revises notice requirements for Paragraph IV filings to include and protect certain proposed formulation, composition, or method of use information.

Excludes an applicants's ability to pay damages from a court's consideration of whether or not to provide injunctive relief before the expiration of the 30 month stay of approval period.

Cosponsors 20

Members who signed on, in the order they did. Signatures ran from Jul 26, 2002 to Oct 1, 2002; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-CAHenry A. WaxmanOriginalJul 26, 2002
D-WAJim McDermottSep 10, 2002
D-NYNita M. LoweySep 10, 2002
D-MILynn N. RiversSep 11, 2002
D-MAJohn W. OlverSep 17, 2002
D-ARMike RossSep 17, 2002
D-FLRobert WexlerSep 17, 2002
D-CAAdam B. SchiffSep 24, 2002
D-MABarney FrankSep 24, 2002
D-MNBetty McCollumSep 24, 2002
D-WABrian BairdSep 24, 2002
D-NYCarolyn B. MaloneySep 24, 2002
D-MIDale E. KildeeSep 24, 2002
D-MIJames A. BarciaSep 24, 2002
D-FLKaren L. ThurmanSep 24, 2002
D-WIThomas M. BarrettSep 24, 2002
D-CABob FilnerSep 26, 2002
D-NJDonald M. PayneSep 26, 2002
D-MOKaren McCarthySep 26, 2002
D-HINeil AbercrombieOct 1, 2002

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jul 26, 2002
Health Subcommittee
Referred Jul 29, 2002

Actions 3

Everything that happened, newest first.

  1. Jul 29, 2002Referred to the Subcommittee on Health.
  2. Jul 26, 2002Introduced in House
  3. Jul 26, 2002Referred to the House Committee on Energy and Commerce.

In the Congressional Record 1

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
HouseDebate and remarks H6261, H6268, H6297Frank Pallone, Jr. D-NJ, Sherrod Brown D-OHSep 17, 2002

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 2

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 107-140EXAMINING ISSUES RELATED TO COMPETITION IN THE PHARMACEUTICAL MARKETPLACE: A REVIEW OF THE FTC REPORT, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION146 pagesEnergy and Commerce CommitteeOct 9, 2002
Serial No. 107-136THE STEEL INDUSTRY LEGACY RELIEF ACT OF 200259 pagesEnergy and Commerce CommitteeSep 10, 2002

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.
Short Titles as Introduced
Prescription Drug Fair Competition Act of 2002

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Jul 26, 2002Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.